

해외 바이오의약품 임상 현황 (2019.11.19~2019.11.25)

한국바이오의약품협회, 2019.11.26.
출처: ClinicalTrials.gov

○ 미국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03970096	Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia	Acute Biphenotypic Leukemia Acute Leukemia of Ambiguous Lineage Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia in Remission Acute Undifferentiated Leukemia Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blastic Plasmacytoid Dendritic Cell Neoplasm Blasts Under 5 Percent of Bone Marrow Nucleated Cells Donor Lymphoblastic Lymphoma Mixed Phenotype Acute Leukemia	Radiation: Total-Body Irradiation Drug: Thiotepa Drug: Fludarabine Drug: Fludarabine Phosphate Drug: Tacrolimus Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs Drug: Methotrexate Biological: Anti-Thymocyte Globulin Drug: Cyclophosphamide Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells Drug: Peripheral Blood Stem Cell	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04128176	Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	Bullous Pemphigoid	Drug: Rituximab combined with Omalizumab	University of California, Davis	Phase 3
NCT04170543	A Phase 2a Diabetic Kidney Disease Study	Diabetic Kidney Disease	Drug: MEDI3506 Drug: Placebo	AstraZeneca	Phase 2
NCT04057833	E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults	Rotator Cuff Tears Muscle Atrophy or Weakness Tendon Rupture - Shoulder Safety Issues	Drug: E-CEL UVEC	Hospital for Special Surgery, New York Angiocrine Bioscience	Phase 1
NCT04142619	Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)	Relapsed/Refractory Multiple Myeloma	Biological: UCARTCS1A	Cellectis S.A.	Phase 1

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04157335	Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)	Nasal Polyposis	Biological: Benralizumab 30 mg Biological: Matched placebo	AstraZeneca	Phase 3

○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04174781	Neoadjuvant Therapy for Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Sintilimab Injection Drug: TACE	Zhejiang University	Phase 2
NCT04170179	Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis	Hepatocellular Carcinoma	Procedure: Systemic chemotherapy Drug: Lenvatinib Drug: Toripalimab	Sun Yat-sen University	Phase 2
NCT04085289	A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants	Healthy	Drug: Galcanezumab Drug: Placebo	Eli Lilly and Company	Phase 1